期刊文献+

不同剂量重组(酵母)乙肝疫苗对小鼠细胞免疫应答的研究 被引量:10

Research on Immunoresponse of Mice by Different Dose Recombinant (yeast) Hepatitis B Vaccine
下载PDF
导出
摘要 目的 :探索不同剂量重组 (酵母 )乙肝疫苗对小鼠细胞免疫调节作用。方法 :将HBsAg免疫Balb/C小鼠一周后取淋巴结制备淋巴细胞悬液 ,经HBsAg刺激培养 4 8h后检测其诱导产生的IL 2、IFN γ的水平 ,另一份细胞同样经HBsAg刺激培养 5 6h后 ,用氚 胸腺嘧啶核苷 (3 H TdR)标记 16h后检测T细胞增殖的水平。用不同剂量HBsAg免疫小鼠后 ,检测血清中抗HBsIgG2a的水平。结果 :中、高剂量组小鼠产生的IL 2、IFN γ、抗HBsIgG2a以及T细胞增殖的水平显著高于低剂量组和对照组。结论 :一定剂量的重组 (酵母 )乙肝疫苗可上调小鼠的细胞免疫功能。 Objective: To study immunoresponse of Balb/C mice with different dose recombinant (yeast) hepatitis B vaccine.Method: After immunized with HBsAg for 7 days,killed the mice and draining lymph nodes were removed and cultured the lymph node cells with 5 μg/ml HBsAg for 48hr, examed the concentration of IL-2 and IFN-γ.On the other hand,cultured the cells for 56hr with HBsAg and labeled with [ 3H]thymidine incorporation for 16hr and examined T cell proliferation. After immunized with different dose HBsAg,examined the lever of IgG2a of anti-HBs of the Balb/C mice.Result: The concentration of IL-2 and IFN-γ,the lever of IgG2a of anti-HBs,T cell proliferation in the group of higher and middle dose HBsAg group were higher than that of control and lower dose group (P< 0.01).Conclusion: higher dose of HBsAg can upregulate celluar immunoresponse in mice.
出处 《中国药师》 CAS 2003年第9期532-534,共3页 China Pharmacist
基金 广东省第 9批科技计划项目基金资助 (编号 :C3 0 40 3 )
关键词 乙肝疫苗 重组(酵母) 细胞因子 Th1类 T细胞增殖 IGG2A recombinant (yeast) hepatitis B vaccine Th 1 cytokine T cell proliferation IgG2a
  • 相关文献

参考文献13

  • 1廖雪雁,梁争论,周绍兵,张弛,邓先模,张华远,李河民.可生物降解高分子乙型肝炎疫苗微球的免疫原性研究[J].中华微生物学和免疫学杂志,2002,22(6):629-634. 被引量:6
  • 2Pol S, Nalpas B, Driss F, et al. Multicenter study group. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B[J]. J Hepatol,2001,34( 6) :917-921.
  • 3Senturk H, Tabazk F, Akdogan M, et al. Therapeutic vaccination in chronic hepatitis B[ J ]. J Gastroenterol Hepatol, 2002,17( 1 ):72-76.
  • 4Sette AD, Oseroff C, Sidney J, et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice[J]. J Immunol, 2001,166(2) : 1389-1397.
  • 5Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide[J]. J Exp Med, 2001,194(6) :833-46.
  • 6Kakimi K, Lane TE, Chisari FV, et al. Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver[J ]. J Immunol, 2001,167(12) : 6701-6705.
  • 7Heintges T, Petry W, Kaldewey M, et al. Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nortresponders with chronic hepatitis B[J]. Dig Dis Sci, 2001,46(4):901-906.
  • 8Livingston BD. Newman M, Crimi C, et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines[J]. Vaccine, 2001,19(32):4652-4660.
  • 9Akbar SM, Abe M, Masumoto T, et al. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells[J]. J Hepatol, 1999,30(5 ) : 755-764.
  • 10Dahmen A, Heraog-Hauff S, Bocher Wo, et al. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B[J]. J Med Virol, 2002,66(4):452-460.

二级参考文献5

共引文献5

同被引文献126

引证文献10

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部